Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00
Provider: S&P Capital IQ Factual Report
$150.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Spectrum Pharmaceuticals Inc Completes Acquisition Of Allos Therapeutics, Inc.


Thursday, 6 Sep 2012 07:00am EDT 

Spectrum Pharmaceuticals Inc announced the completion of the acquisition of Allos Therapeutics, Inc. (Allos), on September 5, 2012 through a short-form merger of Sapphire Acquisition Sub, Inc., a wholly owned subsidiary of Spectrum, with and into Allos with Allos surviving the merger and continuing as a wholly owned subsidiary of Spectrum. Immediately prior to the merger, Spectrum successfully completed cash tender offer to purchase all of the outstanding shares of common stock of Allos. Based on information provided by the depository for the tender offer, a total of 96,259,850 shares were validly tendered and not withdrawn at the expiration of the tender offer (including 2,368,421 shares tendered pursuant to the guaranteed delivery procedures set forth in the Offer to Purchase), representing approximately 89.98% of the outstanding shares of Allos common stock (or approximately 87.77% of such outstanding shares if none of the shares tendered pursuant to the guaranteed delivery procedures are actually delivered). 

Company Quote

7.91
0.01 +0.13%
4:00pm EDT